Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
University of Minnesota · Masonic Cancer Center · +1 more institution
Abstract
Persistent androgen receptor (AR) transcriptional activity underlies resistance to AR-targeted therapy and progression to lethal castration-resistant prostate cancer (CRPC). Recent success in retargeting persistent AR activity with next generation androgen/AR axis inhibitors such as enzalutamide (MDV3100) has validated AR as a master regulator during all stages of disease progression. However, resistance to next generation AR inhibitors limits therapeutic efficacy for many patients. One emerging mechanism of CRPC progression is AR gene rearrangement, promoting synthesis of constitutively active truncated AR splice variants (AR-V) that lack the AR ligand-binding domain. In this study, we show that cells with AR…
Citation impact
- FWCI
- 47.18
- Percentile
- 100%
- References
- 27
Authors
6- YLYingming Li
University of Minnesota, Masonic Cancer Center, Minnesota Supercomputing Institute
- SCSiu Chiu Chan
University of Minnesota, Masonic Cancer Center, Minnesota Supercomputing Institute
- LJLucas J. Brand
University of Minnesota, Masonic Cancer Center
- THTae Hyun Hwang
University of Minnesota, Masonic Cancer Center
- KAKevin A.T. Silverstein
University of Minnesota, Masonic Cancer Center, Minnesota Supercomputing Institute
Topics & keywords
- Enzalutamide
- Androgen receptor
- Prostate cancer
- Cancer research
- Androgen
- Biology
- Internal medicine
- Chemistry
- Good health and well-being